Exact question counts, passing scores, and allowed reference materials vary by testing window and state/agency. Always confirm current rules with the official testing provider.
Sample questions
A biopharmaceutical sponsor submits an original commercial Investigational New Drug (IND) application to FDA CDER for a first-in-human Phase 1 small-molecule oncology study on June 1. On June 26, FDA calls the sponsor to impose a Clinical Hold because the preclinical toxicology package lacks adequate margin-of-safety data to justify the starting dose. Which statement accurately describes the regulatory status under 21 CFR Part 312?
The sponsor may dose subjects on July 1 while addressing toxicology questions, since FDA did not send a written letter within 15 days.
The sponsor may enroll subjects at sites whose IRBs approved the protocol, because IRB approval overrides an oral FDA hold.
The sponsor must withdraw the IND and wait 180 days before filing a new application under another drug name.
The hold takes effect immediately, and no subjects may be dosed until the sponsor files a Complete Response and FDA lifts it.
Show the answer
D. The hold takes effect immediately, and no subjects may be dosed until the sponsor files a Complete Response and FDA lifts it.
Under 21 CFR 312.40(b), an IND goes into effect 30 calendar days after FDA receives it unless FDA notifies the sponsor earlier or imposes a Clinical Hold under 21 CFR 312.42. A Clinical Hold takes effect immediately upon FDA's telephone or rapid communication (followed by a written letter within 30 calendar days). While on hold, no human subjects may be given the investigational drug until the sponsor submits a Complete Response addressing all deficiencies and FDA notifies the sponsor that the hold is lifted (FDA responds within 30 calendar days of receiving the Complete Response).
Reference: 21 CFR 312.40 & 21 CFR 312.42 (IND Effective Date and Clinical Holds)
A sponsor develops an oral targeted therapy for a refractory hematologic malignancy. Phase 2 data show a dramatic durable complete response rate—a surrogate endpoint reasonably likely to predict overall survival—over available therapies, and the sponsor requests an expedited approval pathway based on this surrogate endpoint. Which FDA expedited program matches this approval basis, and what post-approval obligation applies?
Fast Track designation, which grants marketing approval on nonclinical proof-of-concept data without requiring confirmatory studies.
Accelerated Approval, allowing approval on a reasonably likely surrogate endpoint with confirmatory trials.
Breakthrough Therapy designation, which replaces NDA substantial evidence requirements with a single-arm Phase 1 pharmacokinetic cohort.
Priority Review, which cuts the PDUFA review goal from 12 months to 90 days and waives post-marketing pharmacovigilance for 3 years.
Show the answer
B. Accelerated Approval, allowing approval on a reasonably likely surrogate endpoint with confirmatory trials.
Under FDCA Section 506(c) and 21 CFR 314 Subpart H / 601 Subpart E, FDA's Accelerated Approval pathway allows approval of drugs for serious conditions filling an unmet medical need based on a surrogate endpoint reasonably likely to predict clinical benefit (or an intermediate clinical endpoint). Sponsors are required to conduct post-approval confirmatory trials to verify and describe clinical benefit, and FDA holds expedited withdrawal authority (strengthened by FDORA 2022) if benefit is not confirmed or trials are not conducted with due diligence.
Reference: FDCA § 506(c) / 21 CFR 314 Subpart H / FDA Guidance: Expedited Programs for Serious Conditions
An Institutional Review Board has 9 voting members: 6 physician-scientists (all employed by the hospital), 2 nonscientific hospital administrators, and 1 unaffiliated community nonscientist. At a convened meeting reviewing a new Phase 3 trial, 5 physician-scientists attend while all 3 nonscientific members are absent. Furthermore, during expedited review earlier that week, the IRB Chair decided to disapprove a minimal-risk registry protocol. Which statement accurately identifies the 21 CFR Part 56 compliance issues?
Both actions comply because 5 of 9 members forms a majority quorum and the Chair may disapprove expedited submissions.
The convened meeting complies via a voting majority, whereas only the Chair's expedited disapproval violates 21 CFR 56.110.
The expedited disapproval is valid under 21 CFR 56.110, while the meeting fails quorum solely without the unaffiliated member.
Both actions violate 21 CFR 56: quorum requires at least one nonscientist present, and expedited reviewers cannot disapprove studies.
Show the answer
D. Both actions violate 21 CFR 56: quorum requires at least one nonscientist present, and expedited reviewers cannot disapprove studies.
Under 21 CFR 56.108(c), a convened IRB meeting quorum requires a majority of the members INCLUDING at least one member whose primary concerns are in nonscientific areas—having 5 of 9 members with zero nonscientists present fails quorum. Additionally, under 21 CFR 56.110(b), an expedited reviewer may exercise all authorities of the IRB EXCEPT that the reviewer may NOT disapprove the research; disapproval may occur only after full review at a convened IRB meeting.